Solly Chedid, MD

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Solly Chedid, MD, shares insights on optimizing anemia management in patients with lower-risk MDS and outlines remaining unmet needs in treating anemia.

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.